MYOMO, INC. — fact timeline

Joseph M. Manko Jr. was appointed as Class I director at MYOMO, INC..

“the Board appointed Joseph M. Manko Jr. to join the Board, effective on May 9, 2026.”

MYOMO, INC. reported first quarter ended March 31, 2026 results: revenue $10,113,288, net income $3.0 million, EPS $0.07 per share. Guidance reaffirmed.

“Myomo Reports First Quarter 2026 Financial and Operating Results Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today BURLINGTON, Mass. (May 7, 2026) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026.”

MYOMO, INC. updated its the three months and year ended December 31, 2025 guidance (initiated).

“On March 9, 2026, Myomo, Inc, (the "Company") announced its financial results for the fourth quarter and full year ended December 31, 2025.”

MYOMO, INC. issued up to $1,312,500 worth of shares of the Company's common stock of warrant to Avenue Venture Opportunities Fund II, L.P..

“the Company issued to the Lender a warrant to purchase up to $1,312,500 worth of shares of the Company's common stock (the “Warrant”).”

MYOMO, INC. incurred term loan of up to $17.5 million with Avenue Capital Management II, L.P. (administrative agent) and Avenue Venture Opportunities Fund II, L.P. (lender) at the sum of 4.75% and the prime rate as reported in The Wall Street Journal maturing June 1, 2029.

“On November 4, 2025 (the “Closing Date”), Myomo, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”), with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”) and Avenue Venture Opportunities Fund II, L.P., as a lender (the “Lender”). Also on November 4, 2025, the Company entered into a Supplement to the Loan and Security Agreement (the “Supplement” and together with the Loan and Security Agreement, the “Loan Agreement”) with the Agent and the Lender. The Loan Agreement provides for committed term loans in an aggregate principal amount of up to $17.5 million with (a) $12.5 million funded on the Closing Date (“Tranche 1”) and (b) up to $5.0 million to be funded at any time between November 4, 2026 and May 4, 2027, so long as no default or event of default has occurred and is continuing.”

MYOMO, INC. engaged CBIZ CPAs P.C. as its auditor.

“On April 8, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and with the approval of the Audit Committee of the Company’s Board of Directors (the "Board"), the Company engaged CBIZ CPAs as the Company’s independent registered public accounting firm, effective as of April 8, 2025.”

Marcum LLP resigned as auditor of MYOMO, INC..

“On April 8, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and with the approval of the Audit Committee of the Company’s Board of Directors (the "Board"), the Company engaged CBIZ CPAs as the Company’s independent registered public accounting firm, effective as of April 8, 2025.”

Yitzchak Jacobovitz departed as Director at MYOMO, INC..

“Also on April 4, 2025, Mr. Yitzchak Jacobovitz, a member of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that he does not intend to stand for reelection at the Annual Meeting.”

Amy Knapp departed as Director at MYOMO, INC..

“On April 4, 2025, Ms. Amy Knapp, a member of the Board, the Audit Committee of the Board and the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders”

MYOMO, INC. reported first quarter ended March 31, 2024 results: revenue $3.8 million, net income $3.8 million, or $0.10 per share. Guidance raised.

“Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable”

Heather Getz was appointed as Director at MYOMO, INC..

“the Board increased its size from six to seven members and appointed Heather Getz to join the Board, effective on March 26, 2024.”

MYOMO, INC. reported the three months and year ended December 31, 2023 results: revenue $4.8 million, net income $0.07 per share. Guidance initiated.

“by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2023 Financial Results Q4 total revenue of $4.8 million, up 18% over the prior year Addition of Medicare Part B patients to backlog results in record 183 MyoPro orders and insurance authorizations received in Q4, up 87% over the prior”

MYOMO, INC. reported the fourth quarter of 2023 results: revenue in the range of $4.6 million to $4.8 million.

“Revenue for the fourth quarter of 2023 is expected to be in the range of $4.6 million to $4.8 million, an increase of 14% to 19%, compared with the same period a year ago.”

MYOMO, INC. entered into Purchase Agreement with certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company valued at gross proceeds of $6 million (effective 2024-01-16).

“On January 16, 2024, Myomo, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named therein, including certain of the Company’s 5% stockholders and certain directors and employees of the Company, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) (i) 1,354,218 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (each a “Share” and collectively the “Shares”); and (ii) pre-funded warrants in lieu of shares of Common Stock (the “Pre-Funded Warrants”) to purchase 224,730 shares of Common Stock.”

MYOMO, INC. reported the three and nine months ended September 30, 2023 results: revenue Total revenue was $5.1 million, net income Net loss for the third quarter of 2023 was $2.0 million, or $0.06 per share, EPS $0.06 per share.

“--- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30”

MYOMO, INC. terminated common stock purchase agreement with Keystone Capital Partners, LLC valued at $5,000,000 of common stock (effective 2023-08-24).

“On August 24, 2023, Myomo, Inc. (the “Company”) and Keystone Capital Partners, LLC (“Keystone”), by mutual written consent, agreed to terminate the common stock purchase agreement dated August 2, 2022 by and between the Company and Keystone pursuant to which Keystone agreed to purchase from us, from time to time, up to $5,000,000 of our common stock, subject to certain limitations. The Company did not incur any early termination penalties in connection with the early termination of such agreement.”

MYOMO, INC. reported the second quarter ended June 30, 2023 results: revenue $6.0 million.

“EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics Q2 revenue of $6.0 million, including license revenue Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline Begins to build Medicare Part B patient pipeline following”

MYOMO, INC. shareholders approved Approval of Amendment No. 2 to the Myomo 2018 Stock Option and Incentive Plan increasing shares by 1,100,000 at the 2023-06-07 meeting.

“For Against Abstain 8,406,979 1,446,679 51,026”

MYOMO, INC. shareholders approved Ratification of Marcum LLP as independent registered public accounting firm at the 2023-06-07 meeting.

“For Against Abstain 13,882,930 421,711 201,584”

MYOMO, INC. shareholders approved Advisory vote on the frequency of votes on named executive officer compensation at the 2023-06-07 meeting.

“1 Year 2 Years 3 Years Abstain 2,268,300 535,857 7,020,616 79,911”

MYOMO, INC. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2023-06-07 meeting.

“For Against Abstain 8,918,698 962,627 23,359”

MYOMO, INC. shareholders approved Election of Paul R. Gudonis and Thomas F. Kirk as Class III directors at the 2023-06-07 meeting.

“Nominee For Withhold Broker Non-Votes Paul R. Gudonis 9,005,578 899,106 4,601,541 Thomas F. Kirk 8,885,312 1,019,372 4,601,541”

MYOMO, INC. reported financial results for the three months ended March 31, 2023.

“On May 10, 2023, Myomo, Inc, (the "Company") announced its financial results for the first quarter ended March 31, 2023.”

Yitzchak Jacobovitz was appointed as Class II Director at MYOMO, INC..

“The board of directors increased the size of the Board from five to six members and appointed Yitzchak Jacobovitz, selected and nominated by AIGH, as a Class II director effective January 27, 2023”

MYOMO, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-01-11).

“The Company also entered into a Placement Agency Agreement, dated January 11, 2023, by and between the Company and the Placement Agent (the “Placement Agency Agreement”).”

MYOMO, INC. entered into Securities Purchase Agreement with certain investors valued at $6.5 million (effective 2023-01-11).

“On January 11, 2023, Myomo, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver to Investors, in a registered public offering (the “Offering”) (i) 13,169,074 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (each a “Share” and collectively the “Shares”); and (ii) pre-funded warrants in lieu of shares of Common Stock (the “Pre-Funded Warrants”) to purchase 6,830,926 shares of Common Stock.”

MYOMO, INC. reported third quarter ended September 30, 2022 results: revenue $4.0 million, net income $2.8 million, EPS $0.40 per share.

“Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog Third quarter revenue of $4.0 million, up 8% sequentially 130 authorizations and orders results in a record-high backlog of 184 units”